ProKidney has arranged a program that would allow it to sell up to $200 million of its Class A common stock over time through Jefferies. The sales would be made at prevailing market prices or through other permitted transactions, rather than in a single required offering.
The arrangement gives the company access to potential equity financing, but it does not mean ProKidney has raised money or committed to sell shares. Sales can begin only if the company’s shelf registration statement becomes effective.
Key details
- Up to $200 million in potential stock sales: ProKidney may sell shares from time to time through Jefferies under the program. The $200 million is the maximum aggregate offering price, not proceeds already raised.
- No obligation to sell: ProKidney can choose whether to make sales and may suspend the offering at any time.
- Timing depends on registration effectiveness: The company filed a shelf registration statement on October 29, 2026, but said it cannot assure that it will become effective or remain effective. No sales under the program can occur unless it is effective.
- Sales agent compensation: Jefferies may receive a commission of up to 3% of gross proceeds from shares it sells, and ProKidney will reimburse certain expenses.
- Potential share dilution: If ProKidney sells shares, the number of shares outstanding would increase, diluting existing shareholders’ ownership.
- Jefferies’ other work for the company: Jefferies has provided, and may in the future provide, financial advisory and investment-banking services to ProKidney for customary fees and expense reimbursement.